Generate Biomedicines (NASDAQ:GENB) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Generate Biomedicines (NASDAQ:GENB) to a hold rating in a report issued on Wednesday morning,Zacks.com reports.

GENB has been the topic of several other research reports. Wall Street Zen upgraded shares of Generate Biomedicines to a “hold” rating in a report on Saturday, March 14th. Cantor Fitzgerald began coverage on Generate Biomedicines in a research note on Tuesday. They issued an “overweight” rating for the company. Piper Sandler initiated coverage on Generate Biomedicines in a research note on Tuesday. They set an “overweight” rating and a $24.00 price target on the stock. Guggenheim started coverage on Generate Biomedicines in a report on Tuesday. They issued a “buy” rating and a $30.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on Generate Biomedicines in a research note on Tuesday. They issued a “buy” rating and a $26.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Generate Biomedicines currently has a consensus rating of “Moderate Buy” and an average price target of $25.00.

Generate Biomedicines Stock Performance

NASDAQ:GENB opened at $12.85 on Wednesday. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.